Aurora Cannabis Announces Filing of Prospectus Supplement for At-The-Market Offering Program

Executive Summary

• Aurora Cannabis filed a prospectus supplement to establish a new at‑the‑market (ATM) offering program allowing issuance and sale of up to US$100 million of common shares.
• Net proceeds are intended for strategic, accretive purposes, specifically increased cultivation capacity and potential M&A activity.
• The ATM sales will be conducted through TD Securities (USA) LLC under a sales agreement dated February 4 2026 and may be executed on NASDAQ or other U.S. marketplaces at prevailing market prices.

Key Details

• Program Size: Up to US$100 million of common shares may be issued and sold from treasury.
• Use of Proceeds: Targeted for cultivation capacity expansion and mergers & acquisitions (strategic, accretive purposes).
• Sales Mechanism:
• “At‑the‑market distributions” per NI 44‑102 – Shelf Distributions.
• Shares sold on the NASDAQ Capital Market or other U.S. venues at prevailing market price; private negotiated transactions also permitted.
• No sales will be made on Canadian exchanges.
• Sales Agreement: Executed with TD Securities (USA) LLC on February 4 2026.
• Regulatory Filings:
• Prospectus Supplement filed with all Canadian provincial securities regulators (except Quebec) and the U.S. SEC as part of Form F‑10 registration statement under the Multijurisdictional Disclosure System.
• Base Shelf Prospectus originally dated February 14 2025; supplemental documents available on SEDAR+ and EDGAR.
• Forward‑Looking Statements: Include expectations regarding timing/completion of the ATM program and use of proceeds; subject to customary risk factors disclosed in Aurora’s Annual Information Form (June 17 2025).

Notable Quotes

(No executive quotes were provided in the release.)